Imagine facing a diagnosis that looks like a well-known genetic disorder, only to discover the genetic test comes back negative. That's the frustrating reality of MEN1 phenocopies, and it's more common than you might think. A recent national study sheds light on this diagnostic puzzle, offering crucial insights for clinicians and patients alike. This original article, slated for publication in the Journal of Endocrinological Investigation on November 12, 2025, delves into the complexities of these MEN1 'mimics.'
This groundbreaking research, led by Rosaria M. Ruggeri, Elio Benevento, Iderina Hasballa, Erika Maria Grossrubatscher, Roberta Modica, Manuela Albertelli, Bianca Golisano, Vito Guarnieri, Flavia Pugliese, Valentina Guarnotta, Simona Jaafar, Andrea Lania, Antonio Prinzi, Isabella Zanata, Maria Chiara Zatelli, Annamaria Colao, and Antongiulio Faggiano on behalf of the NIKE Group, highlights the challenges of diagnosing and managing patients who present with symptoms suggestive of Multiple Endocrine Neoplasia type 1 (MEN1) but lack the characteristic genetic mutations.
MEN1, for those unfamiliar, is an inherited condition primarily driven by mutations in the MEN1 gene. It typically manifests as a trio of endocrine tumors: primary hyperparathyroidism (PHPT), pancreatic neuroendocrine tumors (PanNETs), and pituitary neuroendocrine tumors (PitNETs). However, a significant portion – between 10% and 30% – of individuals exhibiting these telltale signs don't possess the MEN1 gene mutation. These cases are termed 'phenocopies,' meaning they phenotypically (outwardly) resemble MEN1 but have a different underlying cause.
To better understand these phenocopies, researchers conducted a retrospective multicenter study across ten Italian referral centers. Over five years, they evaluated 240 patients suspected of having MEN1. Of these, 175 were genetically confirmed to have MEN1 (average age 43.2 years, with a standard deviation of 19.7 years; 101 were female), while 65 (27%) were classified as phenocopies (average age 59.9 years, with a standard deviation of 11.6 years; 44 were female). Notice the significant age difference? This is one of the key findings we'll explore further. And this is the part most people miss: the later age of onset in phenocopies can be a crucial diagnostic clue.
Interestingly, the study also investigated mutations in the CDKN1B gene, responsible for MEN4, another rare endocrine neoplasia syndrome. A substantial 70.7% of the phenocopies were also negative for CDKN1B mutations, further solidifying the rarity of MEN4 as an explanation for these MEN1-like cases. But here's where it gets controversial... Could there be other, yet undiscovered, genetic factors at play in these CDKN1B-negative phenocopies?
The study revealed that phenocopies are typically diagnosed one to two decades later than genetically confirmed MEN1 patients (p < 0.0001), reinforcing the age difference as a critical distinguishing factor. While PHPT remained the most common manifestation in both groups (80% in phenocopies vs. 81% in MEN1), the tumor associations differed significantly (p < 0.001). The classic triad of PHPT, PanNETs, and PitNETs was observed in 41% of MEN1 patients but in a mere 1% of phenocopies! In MEN1 patients, PHPT often coincided with NETs (32%), whereas in phenocopies, PHPT was more frequently associated with PitNETs (54%), mirroring the patterns observed in sporadic (non-inherited) tumors. This suggests that many phenocopies might simply represent the coincidental occurrence of common endocrine tumors.
Notably, 11% of phenocopies had a first-degree relative with MEN1-related diseases, and a striking 51% had a personal or family history of other types of cancer. This begs the question: are these familial links purely coincidental, or do they point to shared genetic predispositions or environmental factors that increase the risk of endocrine and other cancers?
In conclusion, this study underscores that MEN1 phenocopies are a relatively common and clinically challenging entity. Their distinct clinical features, particularly the later age of onset and differing tumor associations, along with their frequent family history of cancer, warrant a comprehensive diagnostic approach. The authors recommend offering an extended genetic panel to these patients, beyond just MEN1 and CDKN1B testing, along with regular screening for MEN1-related diseases. This proactive approach is crucial for early detection and management of potential complications.
What do you think? Should genetic testing be even broader, encompassing a wider array of cancer-related genes, in patients suspected of having MEN1 phenocopies? Could lifestyle factors play a larger role than currently appreciated? Share your thoughts and experiences in the comments below!
